Applications of (R)-3-Amino-4-(2-Chlorophenyl)Butanoic Acid Hydrochloride in Industrial Manufacturing

As a direct manufacturer, we supply (R)-3-Amino-4-(2-Chlorophenyl)Butanoic Acid Hydrochloride to several advanced industries with strict process and compliance requirements. This chiral intermediate supports the synthesis of fine chemicals and APIs, enabling downstream producers to meet regulatory, formulation, and performance needs in specialized applications. Each segment below details integration practices, regulatory frameworks, dosing guidance, and typical end-products relevant to industrial users.

1. Pharmaceutical Active Ingredient Synthesis

Pharmaceutical manufacturers employ this compound as a key chiral intermediate in the multi-step synthesis of antiepileptic and neuroactive drug molecules. Its stereospecificity allows process chemists to build complex target APIs under regulatory frameworks demanding full traceability and isomeric purity throughout GMP operations. The intermediate is introduced post-alkylation and prior to final functionalization stages in bulk pharmaceutical manufacturing schemes, where exacting control of stereochemistry and low-level impurities are critical.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU EudraLex Volume 4 (Parts I & II for APIs)
• US FDA 21 CFR Part 211
• Relevant national pharmacopeias for chiral intermediate purity

Typical usage ratio

• 20–35% molar equivalent as building block per overall API batch, adjusted per route yield and desired optical activity

Downstream process integration

• Added during post-coupling stages after initial backbone assembly
• Processed under controlled chiral catalysis and purification to maintain enantiomeric excess
• Quality checked for residual solvents and chiral integrity before conversion to active drug substance

Final product types

• Anticonvulsant active pharmaceutical ingredients
• Chiral neurotherapeutic agents
• Intermediates for further functionalized synthetic drugs

2. Chiral Intermediate in Fine Chemical Production

This compound supports manufacturers producing optically pure building blocks and custom specialty chemicals, where regulatory-driven documentation and consistent quality have direct impacts on customer product performance. Typical users include contract fine chemical producers supplying the agrochemical, advanced material, and research reagent-based sectors. The intermediate enters synthetic processes post-protection and prior to coupling reactions, providing stereospecificity for downstream molecular constructions.

Industry compliance standards

• ISO 9001:2015 Quality Management System
• REACH Regulation (EC) No 1907/2006 (for European importers)
• Dedicated client audit regimes for advanced intermediates
• Custom contract QC methods for chiral purity and residual impurities

Typical usage ratio

• Varies from 10–25% by mass in multistep reactions; typically parameterized based on targeted yield and downstream molecular complexity

Downstream process integration

• Injected after preliminary protection stages in asymmetric synthesis routes
• Isolated at intermediate checkpoints before final refinement or downstream derivatization
• Storage and handling procedures designed to preserve chiral purity until subsequent chemical transformations

Final product types

• Optically active fine chemicals
• Specialty research intermediates for chemical synthesis
• Precursor molecules for agrochemical derivatives

3. Precursor for Research-Grade Analytical Reagents

Producers of laboratory analytical reagents rely on this chiral compound as a high-purity precursor in synthesizing standards used for pharmaceutical and forensic research applications. Such applications demand verified chain of custody, traceable batch documentation, and compliance with international analytical quality protocols. The precursor enters custom synthetic routes at the resolution or derivatization step, enabling the preparation of authentic reference materials.

Industry compliance standards

• ISO 17034:2016 for Reference Material Producers
• ISO/IEC 17025:2017 for Testing and Calibration Laboratories
• CERTISO 22301 for laboratory business continuity (where required)
• National External Quality Assessment Schemes (NEQAS standards)

Typical usage ratio

• Typically 15–50% by weight in research batch sizes, determined by synthesis scale and analytical end-use

Downstream process integration

• Introduced at preparative resolution stage for reference standard manufacturing
• Processed under inert, low-moisture conditions to avoid racemization
• Purified post-derivatization to analytical reference specifications

Final product types

• Certified analytical reference materials
• Pharmacological standard substances for HPLC or GC calibration
• Forensic reagent kits

4. Advanced Custom API Development for Contract Manufacturing Organizations (CMOs)

Contract manufacturing organizations engaged in clinical and post-clinical API production integrate this material as a critical intermediate when developing patient-specific or rare disease drug molecules. The process mandates comprehensive documentation, tailored batch manufacturing records, and full traceability under GMP and quality-by-design (QbD) protocols. The material is introduced at specific chain-elongation or chiral-amination steps to ensure the molecular configuration matches required therapeutics specifications for late-stage clinical supply chains.

Industry compliance standards

• PIC/S Guide to Good Manufacturing Practice for Medicinal Products, PE 009
• US FDA DMF (Drug Master File) submission requirements
• ICH Q11: Development and Manufacture of Drug Substances
• Client-specific batch release and audit protocols

Typical usage ratio

• Batch-specific, usually within 18–30% by calculated theoretical mass in process-scale production, adjusted in accordance with clinical phase API yield requirements

Downstream process integration

• Added after initial assembly or condensation steps within custom synthetic routes
• Processed under closed-system conditions to comply with contamination and cross-batch control
• Subjected to in-process control for identity, purity, and enantiomeric excess before subsequent synthesis steps

Final product types

• Clinical trial and pilot-scale APIs
• Custom small-batch pharmaceutical substances for orphan drugs
• Specialty chiral advanced intermediates for further contract processing